Proposal to list medical devices supplied by Baxter Healthcare Ltd
What we’re proposing
Pharmac is seeking feedback on a proposal to list adhesive, sealant, and haemostat medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 September 2024 supplied by Baxter Healthcare Limited (“Baxter”).
Consultation closes at 4pm, Tuesday 9 July 2024 and feedback can be emailed to kendra.boyes@pharmac.govt.nz
What would the effect be?
From 1 September 2024, medical devices supplied by Baxter in the adhesives, sealants, and haemostats category would be listed under a proposed national agreement for all Health New Zealand | Te Whatu Ora (“Health NZ”) hospitals to purchase under, subject to consultation and approval by Pharmac’s Board or delegate (“Agreement”).
The Agreement would not be for sole supply and Health NZ hospitals could continue to continue to purchase other suppliers’ brands of adhesives, sealants, and haemostats.
The Agreement would supersede any existing Health NZ contracts with Baxter for the products included in the Agreement. Any medical devices listed in the Agreement and purchased by Health NZ hospitals would be in accordance with the terms and conditions, including price, stated in the Agreement effective from the date of listing on the Pharmaceutical Schedule.
Who we think will be interested
- Health NZ staff in a range of different clinical settings including but not limited to:
- Emergency service personnel
- General ward clinicians and nurses
- Operating theatre nurses
- Surgeons
- Procurement and supply chain personnel
- Suppliers and Wholesalers
About these medical devices
Adhesives, sealants, and haemostats are medical devices used in surgical and non-surgical procedures to achieve haemostasis, tissue sealing, fixation and/or wound closure. The products vary, relating to their purpose, function, composition, application and clinical indication. There are adhesive, sealant, and haemostat products used in general surgical applications, as well as products designed and used for specific clinical indications/specialty areas.
Why we’re proposing this
In February 2023 Pharmac issued a Request for Proposals (RFP) for the supply of adhesive, sealant, and haemostat medical devices.
The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
Pharmac has been working with suppliers who responded to the RFP, and were successful in being progressed to contract negotiation, to seek provisional agreements. This proposal is the latest to arise from this process and we expect to consult on further provisional agreements in this category throughout 2024.
Details about our proposal
Pharmac has entered into a provisional agreement with Baxter for the supply of adhesive, sealant, and haemostat medical devices. The proposal would result in listing 60 items from the following brands:
|
|
Further information, including pricing and contractual details, has been provided to Health NZ procurement personnel. Clinicians interested in further detail on what this change means for their Health NZ hospital should engage with their procurement teams.
To provide feedback
Send us an email: kendra.boyes@pharmac.govt.nz by 4pm, Tuesday 9 July 2024.
All feedback received before the closing date will be considered by Pharmac’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.
We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.